New Topical Therapy for Melanoma

Description

Dr. Afsaneh Lavasanifar and collaborators have developed a PCBCL–b-PEG-b-PCBCL (PolyGelTM) hydrogel formulation of silibinin which provides enhanced skin permeabiity and delayed release of silibinin under physiological conditions. In vitro and ex vivo findings suggest this PolyGel formulation of silibinin may be useful as a topical therapy for malignant melanoma.

PolyGel incorporated a relatively high amount of […]

New Dehydropiperidine Compounds for Treatment of Glioblastoma

Description

Glioblastoma multiforme (GBM) is the most aggressive form of brain cancer. Typically treatment involves surgery after which chemotherapy and radiation therapies are used. The medication temozolomide is frequently used as part of chemotherapy. Because of their mode of action, these therapies act mainly on cells that are rapidly dividing. However, there is a small population […]

Novel Therapy for Diabetes, Dyslipidemia and Obesity

Description

Researchers at the University of Alberta have discovered a potential therapy to prevent dyslipidemia, obesity, diabetes and atherosclerosis. The study shows that depletion of an enzyme inhibits phosphatidylcholine synthesis in mice which results in decreased levels of blood cholesterol and triglycerides. Associated mechanisms, which include large increases in the hormone GLP-1 following a meal, protect […]

BioEngineered Adipocytes for the Light-Controlled Release of Insulin

Description

Dr. Peter Light at the University of Alberta has developed genetically engineered adipocytes that secrete significant amounts of bioactive insulin upon exposure to a particular wavelength of blue light. Insulin secretion is specific and very little insulin is secreted in the absence of light. This technology is currently being evaluated as an insulin replacement therapy […]

Novel Bio-markers for Diagnosis and Treatment of Stress

Description
Dr. Dean Befus at the University of Alberta in collaboration with Dr. Thomas Ritz at the Southern Methodist University have identified calcium-binding protein spermatid specific 1 (CABS1) protein forms that can be used as predictive, diagnostic, and prognostic biomarkers for stress in humans.
BACKGROUND
Cortisol is one of the best known and most widely used biomarkers for […]

Inhalable Effervescent Doxorubicin Nanoparticles for Lung Cancer

Description
 

The respiratory tract is an effective administration route for drug delivery to the lung as well as an emerging delivery option for systemic therapeutics. University of Alberta and Alberta Cancer Board researchers have jointly developed a new type of dry-powder inhalable carrier particle with an active release mechanism to disperse therapeutics more effectively. Particle size […]

Therapeutic Hypobaric Normoxia for Hypertension

Description
Researchers at the University of Alberta are developing a non-invasive therapy to alter systemic vascular resistance by using hypobaric normoxia/hyperoxia as an adjuvant to standard medical therapy. Preliminary results studies in mouse models have shown that the therapy enhances arterial vasodilation, increases cardiac output, and lowers effective systemic vascular resistance without changing systemic mean arterial […]

Multifunctional, Atrial Selective Inhibitors for the Treatment of Atrial Fibrillation

Description
Atrial fibrillation (AF) is the most common type of cardiac electrical rhythm disturbance affecting 2 % of the population. While AF does not generally induce sudden cardiac death, it is the primary cause of 15% of strokes and can also cause adverse remodeling of the heart leading to heart failure. 30-40% of patients undergoing coronary […]

Ganglioside GM1 for treatment of Huntington’s Disease

Description
Researchers at the University of Alberta have found that ganglioside metabolism is impaired in Huntington’s disease (HD) and that administration of GM1 restores normal ganglioside levels and decreases HD cell susceptibility to apoptosis. Gangliosides are sialic acid-containing glycosphingolipids that are particularly enriched in the brain and play an essential role in cell signalling. Levels of […]

Small molecule inhibitors of PNKP, a DNA repair enzyme, for cancer therapy

Description
Researchers at the University of Alberta have identified potent small molecule inhibitors of a new DNA repair target, human polynucleotide kinase/phosphatase (PNKP). PNKP is an important enzyme in the DNA break repair pathway that processes and restores both double strand and single strand DNA breaks.  Many aggressive cancers up-regulate DNA repair enzymes and become resistant […]